Thus, the CD40-CD40L pathway can effectively promote systemic anti-tumor immune responses, while targeting CD40 can directly inhibit tumor proliferation, and metastasis, and enhance tumor cells susceptibility. The gene discussed is CD40; the disease is neoplasm.